Penem Antibacterial Drug Class List

Drugs in Drug Class: Penem Antibacterial

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rempex	VABOMERE	meropenem; vaborbactam	POWDER;INTRAVENOUS	209776-001	Aug 29, 2017		RX	Yes	Yes
Rempex	VABOMERE	meropenem; vaborbactam	POWDER;INTRAVENOUS	209776-001	Aug 29, 2017		RX	Yes	Yes
Rempex	VABOMERE	meropenem; vaborbactam	POWDER;INTRAVENOUS	209776-001	Aug 29, 2017		RX	Yes	Yes

Last updated: July 5, 2026

Executive summary

The penem antibacterial market is small versus broader β-lactams, and patent coverage is fragmented across (i) specific penem chemotypes (core heterocycle and side-chain substitutions), (ii) salt/formulation IP (prodrugs, enantiopure forms, parenteral stabilizers), and (iii) manufacturing process IP (key intermediates and crystallization conditions). Ex-diverse competitive pressure comes from (a) carbapenems, (b) β-lactam/β-lactamase inhibitor combinations, and (c) cephalosporins, with the penem niche concentrated in certain geographies and hospital segments.

Without the specific INN or lead products to anchor the Orange Book and litigation record, the patent estate and entry risk cannot be mapped with accuracy at drug-by-drug level.

What counts as a “penem antibacterial” and how is the patent landscape structured?

Penem antibacterials are typically classified by the penem core scaffold and the substitution pattern that drives spectrum, stability, and potency. Patent families for this class generally cluster into three layers:

Core compound protection: scaffold, stereochemistry, and side-chain pattern

Common claim themes include:

• Penem core heterocycle modifications (ring substitution patterns).
• Side-chain variants that tune activity against Gram-positive and Gram-negative pathogens.
• Stereochemistry control, including claims directed to single enantiomers or defined diastereomeric ratios.
• Regimen framing in method-of-use claims for targeted indications (pneumonia, complicated intra-abdominal infection, complicated urinary tract infection).

Salt, polymorph, and formulation protection: stability and delivery

Manufacturing and clinical practicality frequently drive separate filings:

• Pharmaceutically acceptable salts (including specific counterions).
• Polymorph and hydrate forms, often tied to stability in solution or solid state.
• Parenteral dosage form compositions (buffer systems, tonicity agents, cryoprotectants).
• Lyophilized vs. liquid-ready formulations, including reconstitution conditions.

Process IP: intermediates, crystallization, and purification

Process families often have the most enforceable “near-term” leverage:

• Protected intermediate preparation methods.
• Steps that define critical process parameters (C.P.s) to reach desired crystal form and particle size.
• Solvent and purification sequences to control impurities (especially those that impact regulatory filings).

How do market dynamics shape patent term value for penem antibiotics?

The penem segment tends to be acquisition- and stewardship-driven, not volume-led. That creates specific market dynamics that determine whether patent exclusivity is monetized or eroded quickly:

Pricing power depends on formulary access, not just efficacy

Penems compete on:

• Broadness of spectrum vs. comparator carbapenems.
• Practical administration profile (infusion time, stability and cold-chain needs).
• Local guideline adoption and tender cycles.

This affects patent value because formularies can shift before full patent expiry, especially when competitor classes gain reimbursement traction.

Hospital procurement concentrates risk at the institutional level

Patent and exclusivity value is influenced by:

• Contracting frameworks that favor multi-source pricing after at least one competitor enters.
• Rotation policies that reduce “single-driver” reliance.

As a result, patent estate strength matters most in the time window when procurement teams are deciding “switch vs. keep” after first generic or authorized alternative entry.

Resistance patterns shorten effective exclusivity

For β-lactams, resistance evolution can reduce off-label durability and compress the effective economic life of the lead product.

• IP tied to narrow resistance mechanisms can be harder to defend if usage guidance changes.
• Where the penem’s advantage remains guideline-relevant, exclusivity can persist economically even with generic pressure.

Which patents protect penem antibacterial drugs in practice: what to look for?

In practice, “what protects it” requires triaging the estate into enforceability buckets:

1) Active ingredient patents that survive generic entry challenges

The most relevant for generic risk are patents that cover:

• The specific penem compound (or closely defined chemical genus with narrow definition).
• The specific stereochemical form used clinically.
• A specific side-chain or substituent pattern that a generic cannot redesign around.

2) Formulation and polymorph patents that can block a “drop-in” equivalent

A generic can sometimes avoid compound claims but still face:

• Polymorph/crystal form restrictions.
• Salt selection limitations.
• Parenteral composition constraints tied to stability and impurity profile.
• Specific manufacturing steps required to produce the claimed form.

3) Method-of-use claims that can deter “indication carving”

Where a penem is prescribed for a specific indication:

• Method-of-use claims can restrict label-scoped substitution strategies, especially if the generic wants to market only some indications initially.

When does penem antibacterial exclusivity lose protection and what timelines matter?

For US-focused exclusivity analysis, the practical question is: which date comes first for market blocking?

Timeline drivers

• Patent expiration (composition-of-matter and key continuation family members).
• Regulatory exclusivity (NCE, pediatric exclusivity, data exclusivity).
• Orange Book listing strategy (which patents are listed and therefore at risk in ANDA pathways).
• Exclusivity that ends but patent litigation that continues.

Typical outcome in β-lactam classes

The market blocking often hinges on whether compound patents expire before or after the last enforceable formulation/process patent. If formulation or process patents have staggered expirations, “late-life” barriers can extend effective exclusivity even after core compound expiry.

What patent litigation affects penem antibacterial generics and biosimilars?

Penem antibacterials are small-molecule drugs, so biosimilar frameworks do not apply. The relevant litigation and challenge types are:

• ANDA paragraph IV challenges against Orange Book-listed patents.
• Litigation over whether a proposed generic infringes (direct, induced, or contributory).
• Case outcomes tied to claim construction and validity challenges (anticipation/obviousness).

Key litigation impact metrics to track include:

• Whether a settlement includes a date-certain “launch at risk” trigger.
• Whether the NDA holder grants an authorized generic or license.
• Injunction scope (product form, strength, route).

What is the Orange Book status of penem antibacterials and how many patents are typically listed?

Orange Book status is the operational map for ANDA risk. In penem series, Orange Book listings often include:

• Multiple composition-of-matter patents (core compound and stereochemistry).
• Multiple formulation patents (salt, polymorph, lyophilized vs. solution).
• Sometimes device or container closure patents depending on NDA strategy.

The number of listings can be large for a single NDA because continuation practice is common in this chemistry space. The most important feature for investors and licensing teams is not raw count but overlap:

• Compound vs. formulation vs. process separation.
• Whether all listed patents expire together or are staggered.

How do penem antibacterial patent estates compare with carbapenem and β-lactam/β-lactamase inhibitor competition?

Penems compete in therapeutic classes where both clinicians and payers can pivot. Patent estate comparison should be evaluated along three dimensions:

1) Substitutability and guideline stickiness

If a penem is guideline-relevant primarily where certain resistance phenotypes exist, competitors may not fully substitute during early generic waves.

2) Technical barriers to product parity

Formulation stability and impurity controls can create manufacturing friction, especially for lyophilized products or defined crystal forms.

3) Portfolio timing vs. lifecycle management

Some incumbents preserve “late patent” protection via:

• Life-cycle formulation upgrades.
• New salt forms.
• New dosing regimens (method-of-use).
• Jurisdiction-specific filings that complicate legal timelines.

Which companies are challenging penem antibacterial patents and what are the entry risks?

Entry risks depend on who files ANDAs and whether they choose:

• A carve-out launch strategy (partial label).
• A designed-around formulation strategy (non-infringing salt/polymorph).
• A court-led delay strategy (paragraph IV challenge with settlement).

The two risk signatures:

• If a generic maker challenges core compound patents, settlement and launch dates become central.
• If challenges focus on formulation patents, “at-risk” launches can happen faster if compound patents expire earlier or are non-read.

What formulations are protected for penems and how does that affect generic launch scenarios?

Penem generics often face constraints in:

• Salt selection that preserves in-vial stability and impurity thresholds.
• Polymorph and crystallization parameters.
• Reconstitution media and buffer composition.

These formulation specifics can matter because ANDA approvals require bioequivalence and quality equivalence. If a listed patent claims a specific crystalline form or compositional detail, a generic can be blocked until it designs around or litigates successfully.

What manufacturing IP barriers commonly affect penem antibacterials?

Manufacturing bottlenecks that show up in patent litigation:

• Control of impurity profile through specific synthetic routes.
• Crystallization and drying steps that determine particle size distribution and polymorph.
• Solvent system restrictions that appear in process claims.

Even where a generic avoids infringement on the drug substance claim, it can still face process claim assertions if manufacturing reproduces protected steps.

What commercial exposure does the penem patent landscape create?

Commercial exposure is concentrated in:

• High-acuity hospital systems where penem switching is constrained by institutional protocols.
• Indications with clear superiority or resistance-targeting relevance.
• Tender markets where price discounts accelerate substitution after exclusivity breaks.

Portfolio timing and settlement outcomes shape revenue risk:

• If a settlement grants early generic entry to one filer, revenue drops can be immediate even if multiple patents remain active.
• If settlements delay all challengers until a later date, revenue compression can be slower and more predictable.

Key takeaways

• Penem antibacterial IP estates usually split into compound, stereochemistry, formulation/polymorph, and manufacturing process families; generic risk depends on which layer is Orange Book-listed and enforceable.
• Market exclusivity value is driven by hospital procurement dynamics and resistance-guideline stickiness, not just chemical potency.
• The operational path to assess entry risk is Orange Book listing-by-listing (patent count alone is less predictive than overlap and staggered expirations).
• For penems, biosimilar risk is not applicable; the relevant challenge pathway is ANDA with paragraph IV and patent litigation or settlements.

FAQs

1) How do I assess penem antibacterial generic entry risk without knowing the exact NDA?

Use Orange Book listings to identify the last-to-expire enforceable patents by category (compound vs formulation vs process) and compare those dates to likely ANDA paragraph IV settlement triggers.

2) Which patent types most often block an ANDA for a penem antibiotic?

Formulation/polymorph and manufacturing/process patents commonly block “drop-in” parity when a generic cannot match the claimed solid form or manufacturing sequence.

3) Do penems face biosimilar challenges under the FDA?

No. Penem antibacterials are small molecules, so biosimilar frameworks are not applicable.

4) What settlement terms matter most for penem antibacterial revenue forecasting?

Date-certain permitted launch terms and any license scope (strengths, formulations, indications) that determine whether an authorized generic or full label substitution can occur.

5) How does resistance evolution affect penem exclusivity economics?

Shifts in resistance patterns and guideline emphasis can reduce clinical demand durability, compressing the period in which the patent estate translates into net revenue even before legal exclusivity ends.

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-07-05).